Taysha Gene Therapies Inc (TSHA) Stock Price, Quote & News

Company Profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency...

Industry: Biotechnology

Sector: Healthcare

Phone: 214 612 0000

Website: www.tayshagtx.com

Address:

3000 Pegasus Park Drive, Suite 1430, Dallas, United States

Jarvis7424 May. 13 at 1:42 PM

$TSHA many weeks of coiling between $6.6 - $7 👀 I’m ready for that pop to $10+

0 · Reply

BiotechGoldenEra May. 13 at 3:46 AM

$TSHA yabba yabba do

0 · Reply

quickaspeter May. 12 at 4:06 PM

$TSHA Let's go... https://www.marketscreener.com/news/asgct-2026-poster-preclinical-data-supporting-design-of-tsha-102-for-rett-syndrome-ce7f5bdedd8cf323

0 · Reply

quickaspeter May. 12 at 4:04 PM

$TSHA ASGCT 2026 Poster: Preclinical Data Supporting Design of TSHA-102 for Rett syndrome https://ir.tayshagtx.com/static-files/cfbb053d-b5cc-43b2-877f-49e1e1a4df53

0 · Reply

Jarvis7424 May. 8 at 2:54 PM

$TSHA I don’t think people understand the value of 102 🔥

2 · Reply

Jarvis7424 May. 7 at 2:50 PM

$TSHA it’s a hold and wait - could be a wild second half of the year 🔥

0 · Reply

Dark_Horse_Investments May. 6 at 8:10 PM

$TSHA These calls, have the potential to shake things up: this one did just that. No data reveal, a tease of the upcoming 12 month update, yet the Q&A was pointed, W focus on BLA, efficacy, durability, & important questions raised. Sean & Suku, “S&S” dynamic duo, inspire confidence. A few items of note: 1. Cantor gal opener Q&A. As Sean wrapped, Suku stepped in & hammered home why dual stranded construct outperforms full length: superior efficacy, faster clinical improvement, & mechanistic edge the competition can’t match. He’s clearly dissected every preclinical & clinical datapoint in the field, ngne. 2. Downside: 6 mo interim data support accelerated path, but Q&A made clear FDA may seek 12 mo data. Thus, financing appears inevitable. apparently Part B had screening hiccups, likely W MIN impact. Patient selection is Key! 3. Upside: S&S hinted that long term data show deepening responses. Great heading into pivotal update. The 12 mo dataset has the potential to hit like Thor’s hammer!

1 · Reply

Cattitude May. 6 at 7:50 PM

$TSHA flying extremely under the radar, good reads next week sends this to 10

0 · Reply

Jhane13 May. 6 at 2:25 PM

$TSHA All the analysts buying today 😊

0 · Reply

StocktwitsEarnings May. 6 at 1:08 PM

$TSHA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 down -50.00% YoY • Taysha Gene Therapies expects its $276.6 million cash and cash equivalents as of March 31, 2026, to fund operations into 2028, but will require additional capital for R&D and commercialization.

0 · Reply

Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)

May 6, 2026, 8:30 AM EDT - 7 days ago

Taysha Gene Therapies Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 7 days ago

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 1, 2026, 4:05 PM EDT - 12 days ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 29, 2026, 8:00 AM EDT - 14 days ago

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Apr 27, 2026, 5:21 PM EDT - 16 days ago

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

2026-04-16T15:12:14.000Z - 27 days ago

Unusually active option classes on open April 16th

BULL HIMS NFLX NRGV NUAI PEP QBTS

2026-04-06T11:09:44.000Z - 5 weeks ago

Taysha Gene Therapies price target raised to $17 from $14 at Canaccord

Mar 19, 2026, 8:30 AM EDT - 7 weeks ago

Taysha Gene Therapies Earnings Call Transcript: Q4 2025

2026-03-19T12:11:24.000Z - 7 weeks ago

Taysha Gene Therapies reports 2025 EPS (34c), consensus (34c)

Mar 19, 2026, 8:00 AM EDT - 7 weeks ago

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

2026-03-17T20:50:19.000Z - 2 months ago

Taysha Gene Therapies management to meet with Cantor

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

2026-03-06T13:11:42.000Z - 2 months ago

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

2026-02-06T13:06:48.000Z - 3 months ago

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

Jan 22, 2026, 10:26 AM EST - 3 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

2026-01-06T13:15:19.000Z - 4 months ago

Taysha Gene Therapies announces progress across TSHA-102

Jan 6, 2026, 8:00 AM EST - 4 months ago

Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

2026-01-05T12:41:20.000Z - 4 months ago

Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo

2025-12-04T10:15:11.000Z - 5 months ago

Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs

2025-11-21T14:40:43.000Z - 6 months ago

Taysha price target raised to $19 from $13 at Cantor Fitzgerald

2025-11-05T10:55:37.000Z - 6 months ago

Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP

2025-11-04T13:35:50.000Z - 6 months ago

Taysha Gene Therapies files automatic mixed securities shelf

Nov 4, 2025, 8:30 AM EST - 6 months ago

Taysha Gene Therapies Earnings Call Transcript: Q3 2025

2025-11-04T12:11:03.000Z - 6 months ago

Taysha Gene Therapies reports Q3 EPS (9c), consensus (9c)

2025-11-04T12:10:52.000Z - 6 months ago

Taysha Gene Therapies sees cash runway into 2028

Nov 4, 2025, 7:00 AM EST - 6 months ago

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

2025-10-20T20:21:03.000Z - 7 months ago

Taysha Gene Therapies initiated with a Strong Buy at Raymond James

2025-10-16T20:10:16.000Z - 7 months ago

Taysha Gene Therapies regains full rights to TSHA-102 program

Oct 16, 2025, 4:01 PM EDT - 7 months ago

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

Oct 9, 2025, 8:00 AM EDT - 7 months ago

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Oct 2, 2025, 8:00 AM EDT - 7 months ago

Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome

Aug 12, 2025, 8:30 AM EDT - 9 months ago

Taysha Gene Therapies Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:01 AM EDT - 9 months ago

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 4:05 PM EDT - 10 months ago

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

Jun 3, 2025, 5:17 PM EDT - 1 year ago

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

May 28, 2025, 10:40 PM EDT - 1 year ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 4:02 PM EDT - 1 year ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

May 15, 2025, 8:30 AM EDT - 1 year ago

Taysha Gene Therapies Earnings Call Transcript: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Mar 31, 2025, 2:25 PM EDT - 1 year ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB SRPT XBI

Feb 26, 2025, 8:30 AM EST - 1 year ago

Taysha Gene Therapies Earnings Call Transcript: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Feb 19, 2025, 8:00 AM EST - 1 year ago

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Nov 13, 2024, 4:30 PM EST - 1 year ago

Taysha Gene Therapies Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Taysha Gene Therapies Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:01 AM EDT - 1 year ago

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Transcript: Status Update

Jun 18, 2024, 7:30 AM EDT - 2 years ago

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Jun 12, 2024, 7:00 AM EDT - 2 years ago

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

May 14, 2024, 4:30 PM EDT - 2 years ago

Taysha Gene Therapies Earnings Call Transcript: Q1 2024

May 14, 2024, 4:01 PM EDT - 2 years ago

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 4:05 PM EDT - 2 years ago

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

May 2, 2024, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Taysha Gene Therapies Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:01 PM EDT - 2 years ago

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Mar 14, 2024, 4:26 PM EDT - 2 years ago

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Feb 29, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Feb 15, 2024, 4:01 PM EST - 2 years ago

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Jan 22, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Jan 10, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Dec 19, 2023, 7:30 AM EST - 2 years ago

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

TRIN

Nov 29, 2023, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Nov 14, 2023, 4:30 PM EST - 2 years ago

Taysha Gene Therapies Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:08 PM EST - 2 years ago

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 7, 2023, 8:00 AM EST - 2 years ago

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Sep 19, 2023, 4:01 PM EDT - 2 years ago

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

Aug 24, 2023, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Aug 21, 2023, 11:28 AM EDT - 2 years ago

GordonMD® Invests in Private Placement for Taysha Gene Therapies

Aug 14, 2023, 7:02 AM EDT - 2 years ago

Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results

Jarvis7424 May. 13 at 1:42 PM

$TSHA many weeks of coiling between $6.6 - $7 👀 I’m ready for that pop to $10+

0 · Reply

BiotechGoldenEra May. 13 at 3:46 AM

$TSHA yabba yabba do

0 · Reply

quickaspeter May. 12 at 4:06 PM

$TSHA Let's go... https://www.marketscreener.com/news/asgct-2026-poster-preclinical-data-supporting-design-of-tsha-102-for-rett-syndrome-ce7f5bdedd8cf323

0 · Reply

quickaspeter May. 12 at 4:04 PM

$TSHA ASGCT 2026 Poster: Preclinical Data Supporting Design of TSHA-102 for Rett syndrome https://ir.tayshagtx.com/static-files/cfbb053d-b5cc-43b2-877f-49e1e1a4df53

0 · Reply

Jarvis7424 May. 8 at 2:54 PM

$TSHA I don’t think people understand the value of 102 🔥

2 · Reply

Jarvis7424 May. 7 at 2:50 PM

$TSHA it’s a hold and wait - could be a wild second half of the year 🔥

0 · Reply

Dark_Horse_Investments May. 6 at 8:10 PM

1 · Reply

Cattitude May. 6 at 7:50 PM

$TSHA flying extremely under the radar, good reads next week sends this to 10

0 · Reply

Jhane13 May. 6 at 2:25 PM

$TSHA All the analysts buying today 😊

0 · Reply

StocktwitsEarnings May. 6 at 1:08 PM

0 · Reply

Jarvis7424 May. 6 at 1:01 PM

$TSHA really good update

1 · Reply

stockmoe12 May. 6 at 10:57 AM

$TSHA 10+

1 · Reply

Vansauber May. 6 at 5:19 AM

$PACB go Boom Boom ✨✨ Ming will be eating crickets Check out this two year reverse head and shoulders 🐂🐂🐂 $SPY $XBI $HALO $TSHA

1 · Reply

stockmoe12 May. 6 at 3:48 AM

$TSHA

0 · Reply

OldTimer21 May. 5 at 9:05 PM

$TSHA Let tomorrow morning bring the good news to blow the top off of this!

0 · Reply

Jarvis7424 May. 5 at 8:03 PM

$TSHA BOOOOM. Great close! Lets see what tomorrow brings

0 · Reply

Dark_Horse_Investments May. 5 at 7:14 PM

$TSHA How do we feel about our competitor poster event seeking to "demystify the skull drill" procedure over intrathecal lumbar injection (delivery mechanism used by TSHA - this is akin to epidural)? The announcement describes the following: "Preclinical data will show that ICV administration resulted in greater biodistribution to brain regions central to Rett syndrome pathophysiology, compared to intrathecal‑lumbar administration". Welcome any substantive reactions! We seek to perhaps identify any overlooked shortcomings or attributes on the delivery procedures of each therapy. We have our view that minigene is not only faster acting over weeks & months over single stranded full gene used by NGNE but also that the procedure can be administered virtually at any regular clinic, whereas NGNE is a full surgical interventional procedure. This KEY differentiatior which opens the door for TSHA to gain fastrack adoption... Stay long & discipled my friends! https://ir.neurogene.com/node/9396/pdf

1 · Reply

Jarvis7424 May. 5 at 4:22 PM

$TSHA tomorrow will be interesting

1 · Reply

quickaspeter May. 5 at 2:30 PM

$TSHA Taysha is set to present preclinical data on its TSHA-102 gene therapy for Rett syndrome on May 14 ASGCT meeting in Boston. The data indicates that the self-complementary AAV9 vector achieved significantly higher protein expression in cell models compared to a single-stranded version. Canaccord raised its price target for Taysha Gene Therapies to $17, maintaining a Buy rating, following progress in the company’s REVEAL and ASPIRE trials. Cantor Fitzgerald also reiterated an Overweight rating with a $19 price target, highlighting positive Phase 1/2 data where 83% of patients met responder criteria. Jefferies increased its price target to $13 from $11, Raymond James reiterated a Strong Buy with a $13 price target, expressing confidence in Taysha’s management and trial progress. The company’s pivotal trial enrollment is expected to conclude in the second quarter, with plans to file on 6-month REVEAL Part B data. https://www.investing.com/news/company-news/taysha-gene-therapies-stock-hits-52week-high-at-677-usd-93CH-4659313

0 · Reply

BiotechGoldenEra May. 4 at 1:13 AM

$TSHA earnings!

0 · Reply

Jarvis7424 May. 3 at 9:00 PM

$TSHA HUGE week ahead!

0 · Reply

Jhane13 May. 1 at 9:57 PM

$TSHA Who has a 50,000 share bid on $6.30, that’s crazy

1 · Reply

Market Cap	1.96B
Revenue (ttm)	9.77M
Net Income (ttm)	-109.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,115.66%
Debt to Equity Ratio	0.20

Volume	3,497,515
Avg Vol	2,881,506
Day's Range	N/A - N/A
Shares Out	287.36M
Stochastic %K	59%
Beta	1.25
Analysts	Strong Sell
Price Target	$11.86